
Sign up to save your podcasts
Or


At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.
In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.
From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4.1
1212 ratings
At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.
In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.
From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.

3,217 Listeners

1,720 Listeners

4,345 Listeners

2,201 Listeners

406 Listeners

1,967 Listeners

353 Listeners

1,657 Listeners

145 Listeners

96 Listeners

3,976 Listeners

1,425 Listeners

337 Listeners

34 Listeners

170 Listeners